Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> Pembrolizumab [1374853-91-4]

Pembrolizumab [1374853-91-4]

Imprimir Imprimir
Please log in

Referência HY-P9902-1mg

Tamanho : 1mg

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 1374853-91-4

This product is a controlled substance and not for sale in your territory.

Based on 14 publication(s) in Google Scholar

Description

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Isotype

Human IgG4 kappa
Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control
Species

Humanized
IC50 & Target

IC50: 0.6 nM (PD-1)
In Vitro

Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pembrolizumab Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: αROR1-CAR T and A549 cells
Concentration: 10 μg/mL
Incubation Time: Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days.
Result: Enhanced αROR1-CAR T killing of A549 lung cancer cells under elevated pressure.

Apoptosis Analysis[2]

Cell Line: A549 cells
Concentration: 10 μg/mL
Incubation Time:
Result: Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity.
In Vivo

Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-week-old male BALB/c athymic nude mice[2]
Dosage: 5 mg/kg
Administration: Pembrolizumab (5 mg/kg; Intravenous injection; Once)
Result: Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells.
Essai clinique
CAS No.

1374853-91-4
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Pembrolizumab]
Livraison

Shipping with dry ice.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
  • Loaded PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) on AHC2 biosensor, can bind Pembrolizumab with an affinity constant of 1.898E-09 M as determined in BLI assay.
  • Immobilized PD-1 Protein, Human can bind Pembrolizumab. The EC50 for this effect is 1.8 ng/mL.
Pureté et documentation

Purity: 99.06%

SDS (251 KB)

COA (291 KB)

Inhibitory Antibodies User Guide (602 KB)
Références

  • [1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.  [Content Brief]

    [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep  [Content Brief]

    [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.  [Content Brief]

  • [1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep

    [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.

    [4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pembrolizumab Related Classifications

  • Inhibitory Antibodies
  • Immunology/Inflammation
  • PD-1/PD-L1

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs

Keywords:

Pembrolizumab1374853-91-4MK-3475 LambrolizumabMK3475MK 3475PD-1/PD-L1PD-1/Programmed death-ligand 1PD-1 inhibitorIgG4 antibody cancerimmunologyInhibitorinhibitorinhibit

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT
T9902-1mg
Atezolizumab [1380723-44-3]
 1mg